Leap Therapeutics Q2 2024 Earnings Report $3.36 +0.01 (+0.30%) As of 04:00 PM Eastern Earnings HistoryForecast Leap Therapeutics EPS ResultsActual EPS-$0.52Consensus EPS -$0.42Beat/MissMissed by -$0.10One Year Ago EPSN/ALeap Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ALeap Therapeutics Announcement DetailsQuarterQ2 2024Date8/12/2024TimeN/AConference Call ResourcesLPTX Earnings History Leap Therapeutics Earnings HeadlinesLeap Therapeutics: A Buy On Near-Term Data Catalysts In Stomach And Colon CancerJanuary 6 at 7:08 AM | seekingalpha.comLeap Therapeutics to Participate at the 43rd Annual J.P. Morgan Healthcare ConferenceJanuary 6 at 7:00 AM | prnewswire.comBorn out of bankruptcy, it’s produced 50% per year… There is a wealth phenomenon that has delivered 50% returns per year, on average… And now that Trump is back in office, will likely continue to outperform every other asset by a wide margin. January 6, 2025 | Porter & Company (Ad)Amarin (NASDAQ:AMRN) & Leap Therapeutics (NASDAQ:LPTX) Critical AnalysisJanuary 2, 2025 | americanbankingnews.comLeap Therapeutics to Participate at Piper Sandler 36th Annual Healthcare ConferenceNovember 26, 2024 | prnewswire.comBuy Recommendation for Leap Therapeutics: Promising Phase 2 Trial Developments and Stable Financial OutlookNovember 15, 2024 | markets.businessinsider.comSee More Leap Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Leap Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Leap Therapeutics and other key companies, straight to your email. Email Address About Leap TherapeuticsLeap Therapeutics (NASDAQ:LPTX), a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501. Leap Therapeutics, Inc. has an option and license agreement with NovaRock, Adimab, and BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.View Leap Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles S&P 500 Earnings Set to Shine: January's Critical Market TestCiena Rebounds: AI and Strong Guidance Drive Post-Earnings SurgeHistory Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Upcoming Earnings Schlumberger (1/17/2025)Procter & Gamble (1/22/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
